Standout Papers

Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That ... 2001 2026 2009 2017 8.3k
  1. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2 (2001)
    Dennis J. Slamon, Brian Leyland‐Jones et al. New England Journal of Medicine
  2. Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes (2012)
    Gϋnter von Minckwitz, Michael Untch et al. Journal of Clinical Oncology
  3. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation (2018)
    Jennifer K. Litton, Hope S. Rugo et al. New England Journal of Medicine
  4. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort (2010)
    Luca Gianni, W. Eiermann et al. The Lancet
  5. Recommendations From an International Expert Panel on the Use of Neoadjuvant (Primary) Systemic Treatment of Operable Breast Cancer: An Update (2006)
    Manfred Kaufmann, Gabriel N. Hortobágyi et al. Journal of Clinical Oncology
  6. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study (2001)
    W. Eiermann, Stefan Paepke et al. Annals of Oncology
  7. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial (2020)
    Jennifer K. Litton, Sara A. Hurvitz et al. Annals of Oncology

Immediate Impact

5 by Nobel laureates 17 from Science/Nature 241 standout
Sub-graph 1 of 14

Citing Papers

Deciphering breast cancer: from biology to the clinic
2023 Standout
Tumour circular RNAs elicit anti-tumour immunity by encoding cryptic peptides
2023 StandoutNature
25 intermediate papers

Works of W. Eiermann being referenced

The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use
2012
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
2012 Standout
and 13 more

Author Peers

Author Last Decade Papers Cites
W. Eiermann 16006 9766 3262 5692 223 23.2k
Steven Shak 16418 11027 3049 5893 133 27.6k
Edith A. Perez 20395 10865 4345 4280 395 29.5k
Sandra M. Swain 15005 7045 1442 4787 334 22.7k
Ana M. González-Angulo 14849 11118 2507 2655 278 24.6k
Michael F. Press 19794 8487 3740 8968 222 29.9k
Gϋnter von Minckwitz 16061 12844 2157 3976 428 24.4k
Michael Untch 12268 9834 1225 3758 537 19.1k
Louis Fehrenbacher 24845 7832 2624 4437 156 35.2k
Charles E. Geyer 11083 8452 1569 3005 180 15.9k
Luca Gianni 19941 8116 1035 5586 305 29.8k

All Works

Loading papers...

Rankless by CCL
2026